Molecule News and Research

RSS

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer.

17 Jun 2010

UC researchers receive $2.3M grant to develop user-friendly diagnostics for influenza virus

Researchers at the University of Cincinnati have received a five-year grant to develop rapid, robust, user-friendly diagnostics for influenza virus. An interdisciplinary team of scientists has received a $2.3 million dollar grant from the National Institute for Allergy and Infectious Diseases, one of the National Institutes of Health. The name of the grant is "Glycan Receptor Mimics for Rapid Detection, Typing, and Susceptibility Testing of Influenza."

17 Jun 2010

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.

17 Jun 2010

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

Identification of a key player in a signaling pathway involved in the development of melanoma - the deadliest form of skin cancer - may offer hope for new targeted melanoma therapies.

16 Jun 2010

NSF awards Florida State University $17.5M grant to build 21-tesla magnet system for large molecule analyses

The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.

16 Jun 2010

University of Montreal scientists discover free radical mechanism to viral invasion

Canadian researchers have discovered a new way the body combats respiratory viral infections. In the prestigious journal PLoS Pathogens, scientists from the University of Montreal and the University of Montreal Hospital Research Center explain how the NOX2 molecule, an enzyme that generates a burst of highly reactive oxygen derivatives (or free radicals), activates defense genes and molecules when viruses invade lung cells.

16 Jun 2010

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

15 Jun 2010

Researchers study how APOE4 becomes a potent risk factor for Alzheimer's disease

A molecule implicated in Alzheimer's disease interferes with brain cells by making them unable to "recycle" the surface receptors that respond to incoming signals, researchers at UT Southwestern Medical Center have found.

15 Jun 2010

CLC-5 protein plays active part in inherited kidney disorder: Scientists

Scientists from the University of Leeds have discovered the mechanisms of a protein known to play an active part in the inherited kidney disorder, Dent's disease. The findings provide a new focus for future therapies for the disease, for which there is currently no cure.

15 Jun 2010

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.

14 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions.

14 Jun 2010

Researchers discover key factor in beading mechanism

Researchers at Rice University, Purdue University and the Massachusetts Institute of Technology have solved a long-standing mystery about why some fluids containing polymers -- including saliva -- form beads when they are stretched and others do not.

14 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

ViroStatics, Vichem Chemie partner to discover new AV-HALT drugs

ViroStatics, srl, an Italian-US biopharmaceutical company today announced the formation of a strategic partnership with Vichem Chemie of Budapest, Hungary to identify, synthesize, screen, and develop the next generation of AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) for the treatment of HIV/AIDS and other chronic diseases.

11 Jun 2010

Research may lead to better treatments for depression and substance abuse

In what has been hailed as a breakthrough, scientists from Columbia University Medical Center and Weill Cornell Medical College have outlined the molecular mechanism of membrane transport. The research shows how a protein transforms its shape to transport substances across the cell membrane in order to regulate transmission of the brain's messages across the synaptic gap from one neuron to another.

11 Jun 2010

Pfizer to join SGC-led collaboration to generate chemical probes for proteins involved in epigenetic signalling

The Structural Genomics Consortium (SGC) and Pfizer today announced that Pfizer will join the SGC-led public-private collaboration to generate small molecule inhibitors - "chemical probes" - for proteins involved in epigenetic signalling.

11 Jun 2010

Study identifies mechanism that interrupts normal p53 gene function leading to tumor development

The p53 gene has been a well-documented player in the prevention of tumors. It is considered the most frequently mutated gene in human tumors with more than half harboring p53 mutations (Bennett et al., 1999). These mutations often can be caused by disruption in normal p53 function.

11 Jun 2010

StemCells' GS2-M cell culture media formulation enhances pluripotency of human ES, iPS cells

StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.

10 Jun 2010

Nativis awarded patents in Japan, China, India for drug signal technology

Nativis, Inc., a La Jolla, Calif.-based life science company, has been issued patents in Japan, China and India for its innovative technology that captures the unique signals of approved drugs at the atomic level and then delivers the signal in a solution to treat serious illnesses. The technology, which also has U.S., Canadian and Australian patents, promises to transform the treatment of diseases, including those for which there are no known cures, such as brain cancer.

10 Jun 2010

Molecule News and Research

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

UC researchers receive $2.3M grant to develop user-friendly diagnostics for influenza virus

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

NSF awards Florida State University $17.5M grant to build 21-tesla magnet system for large molecule analyses

University of Montreal scientists discover free radical mechanism to viral invasion

AMRI announces acquisition of Hyaluron

Researchers study how APOE4 becomes a potent risk factor for Alzheimer's disease

CLC-5 protein plays active part in inherited kidney disorder: Scientists

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Researchers discover key factor in beading mechanism

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

ViroStatics, Vichem Chemie partner to discover new AV-HALT drugs

Research may lead to better treatments for depression and substance abuse

Pfizer to join SGC-led collaboration to generate chemical probes for proteins involved in epigenetic signalling

Study identifies mechanism that interrupts normal p53 gene function leading to tumor development

StemCells' GS2-M cell culture media formulation enhances pluripotency of human ES, iPS cells

Nativis awarded patents in Japan, China, India for drug signal technology

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News